Atypical antipsychotics in the treatment of mania

A meta-analysis of randomized, placebo-controlled trials

Roy H. Perils, Jeffrey A. Welge, Lana A. Vornik, Robert M A Hirschfeld, Paul E. Keck

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Background: Randomized, controlled trials have demonstrated efficacy for atypical antipsychotics in the treatment of mania in bipolar disorder, either as monotherapy or adjunctive treatment. However, there are no published comparisons of individual atypical antipsychotics for mania. Data Sources and Study Selection: We conducted a systematic review and meta-analysis of randomized, placebo-controlled monotherapy and adjunctive therapy trials of atypical antipsychotics for acute bipolar mania. Studies published through 2004 were identified using searches of PubMed/MEDLINE with the search terms mania, placebo, and each of the atypical antipsychotics, limited to randomized, controlled clinical trials; review of abstracts from the 2003 meetings of the American College of Neuropsychiatry, American Psychiatric Association, and International Conference on Bipolar Disorder; and consultations with study investigators and representatives of pharmaceutical companies that market atypical antipsychotics. Data Extraction: Analyses were performed on the changes in Young Mania Rating Scale or Mania Rating Scale total scores from baseline to endpoint, using last observation carried forward and computing the difference in change scores between each drug and its corresponding placebo arm. A random-effects model with fixed drug effects was used to combine the studies and make comparisons of the antipsychotics to each other and to placebo. Data Synthesis: Data from 12 placebo-controlled monotherapy and 6 placebo-controlled adjunctive therapy trials involving a total of 4304 subjects (including 1750 placebo-treated subjects) with bipolar mania were obtained. Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone all demonstrated significant efficacy in monotherapy (i.e., all confidence intervals exclude zero). However, after adjusting for multiple comparisons, pairwise comparisons of individual effects identified no significant differences in efficacy among antipsychotics. Magnitude of improvement was similar whether the antipsychotic was utilized as monotherapy or adjunctive therapy. Conclusions: The 5 newer atypical antipsychotics were all superior to placebo in the treatment of bipolar mania. For monotherapy and add-on therapy, cross-trial comparisons suggest that differences in acute efficacy between the drugs, if any, are likely to be small.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalJournal of Clinical Psychiatry
Volume67
Issue number4
StatePublished - Apr 2006

Fingerprint

Bipolar Disorder
Antipsychotic Agents
Meta-Analysis
Randomized Controlled Trials
Placebos
Therapeutics
olanzapine
Pharmaceutical Preparations
Neuropsychiatry
Risperidone
Information Storage and Retrieval
PubMed
MEDLINE
Referral and Consultation
Research Personnel
Observation
Confidence Intervals

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Perils, R. H., Welge, J. A., Vornik, L. A., Hirschfeld, R. M. A., & Keck, P. E. (2006). Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry, 67(4), 509-516.

Atypical antipsychotics in the treatment of mania : A meta-analysis of randomized, placebo-controlled trials. / Perils, Roy H.; Welge, Jeffrey A.; Vornik, Lana A.; Hirschfeld, Robert M A; Keck, Paul E.

In: Journal of Clinical Psychiatry, Vol. 67, No. 4, 04.2006, p. 509-516.

Research output: Contribution to journalArticle

Perils, RH, Welge, JA, Vornik, LA, Hirschfeld, RMA & Keck, PE 2006, 'Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials', Journal of Clinical Psychiatry, vol. 67, no. 4, pp. 509-516.
Perils, Roy H. ; Welge, Jeffrey A. ; Vornik, Lana A. ; Hirschfeld, Robert M A ; Keck, Paul E. / Atypical antipsychotics in the treatment of mania : A meta-analysis of randomized, placebo-controlled trials. In: Journal of Clinical Psychiatry. 2006 ; Vol. 67, No. 4. pp. 509-516.
@article{de212d31a8b143faacd0f1849ce1987f,
title = "Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials",
abstract = "Background: Randomized, controlled trials have demonstrated efficacy for atypical antipsychotics in the treatment of mania in bipolar disorder, either as monotherapy or adjunctive treatment. However, there are no published comparisons of individual atypical antipsychotics for mania. Data Sources and Study Selection: We conducted a systematic review and meta-analysis of randomized, placebo-controlled monotherapy and adjunctive therapy trials of atypical antipsychotics for acute bipolar mania. Studies published through 2004 were identified using searches of PubMed/MEDLINE with the search terms mania, placebo, and each of the atypical antipsychotics, limited to randomized, controlled clinical trials; review of abstracts from the 2003 meetings of the American College of Neuropsychiatry, American Psychiatric Association, and International Conference on Bipolar Disorder; and consultations with study investigators and representatives of pharmaceutical companies that market atypical antipsychotics. Data Extraction: Analyses were performed on the changes in Young Mania Rating Scale or Mania Rating Scale total scores from baseline to endpoint, using last observation carried forward and computing the difference in change scores between each drug and its corresponding placebo arm. A random-effects model with fixed drug effects was used to combine the studies and make comparisons of the antipsychotics to each other and to placebo. Data Synthesis: Data from 12 placebo-controlled monotherapy and 6 placebo-controlled adjunctive therapy trials involving a total of 4304 subjects (including 1750 placebo-treated subjects) with bipolar mania were obtained. Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone all demonstrated significant efficacy in monotherapy (i.e., all confidence intervals exclude zero). However, after adjusting for multiple comparisons, pairwise comparisons of individual effects identified no significant differences in efficacy among antipsychotics. Magnitude of improvement was similar whether the antipsychotic was utilized as monotherapy or adjunctive therapy. Conclusions: The 5 newer atypical antipsychotics were all superior to placebo in the treatment of bipolar mania. For monotherapy and add-on therapy, cross-trial comparisons suggest that differences in acute efficacy between the drugs, if any, are likely to be small.",
author = "Perils, {Roy H.} and Welge, {Jeffrey A.} and Vornik, {Lana A.} and Hirschfeld, {Robert M A} and Keck, {Paul E.}",
year = "2006",
month = "4",
language = "English (US)",
volume = "67",
pages = "509--516",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Atypical antipsychotics in the treatment of mania

T2 - A meta-analysis of randomized, placebo-controlled trials

AU - Perils, Roy H.

AU - Welge, Jeffrey A.

AU - Vornik, Lana A.

AU - Hirschfeld, Robert M A

AU - Keck, Paul E.

PY - 2006/4

Y1 - 2006/4

N2 - Background: Randomized, controlled trials have demonstrated efficacy for atypical antipsychotics in the treatment of mania in bipolar disorder, either as monotherapy or adjunctive treatment. However, there are no published comparisons of individual atypical antipsychotics for mania. Data Sources and Study Selection: We conducted a systematic review and meta-analysis of randomized, placebo-controlled monotherapy and adjunctive therapy trials of atypical antipsychotics for acute bipolar mania. Studies published through 2004 were identified using searches of PubMed/MEDLINE with the search terms mania, placebo, and each of the atypical antipsychotics, limited to randomized, controlled clinical trials; review of abstracts from the 2003 meetings of the American College of Neuropsychiatry, American Psychiatric Association, and International Conference on Bipolar Disorder; and consultations with study investigators and representatives of pharmaceutical companies that market atypical antipsychotics. Data Extraction: Analyses were performed on the changes in Young Mania Rating Scale or Mania Rating Scale total scores from baseline to endpoint, using last observation carried forward and computing the difference in change scores between each drug and its corresponding placebo arm. A random-effects model with fixed drug effects was used to combine the studies and make comparisons of the antipsychotics to each other and to placebo. Data Synthesis: Data from 12 placebo-controlled monotherapy and 6 placebo-controlled adjunctive therapy trials involving a total of 4304 subjects (including 1750 placebo-treated subjects) with bipolar mania were obtained. Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone all demonstrated significant efficacy in monotherapy (i.e., all confidence intervals exclude zero). However, after adjusting for multiple comparisons, pairwise comparisons of individual effects identified no significant differences in efficacy among antipsychotics. Magnitude of improvement was similar whether the antipsychotic was utilized as monotherapy or adjunctive therapy. Conclusions: The 5 newer atypical antipsychotics were all superior to placebo in the treatment of bipolar mania. For monotherapy and add-on therapy, cross-trial comparisons suggest that differences in acute efficacy between the drugs, if any, are likely to be small.

AB - Background: Randomized, controlled trials have demonstrated efficacy for atypical antipsychotics in the treatment of mania in bipolar disorder, either as monotherapy or adjunctive treatment. However, there are no published comparisons of individual atypical antipsychotics for mania. Data Sources and Study Selection: We conducted a systematic review and meta-analysis of randomized, placebo-controlled monotherapy and adjunctive therapy trials of atypical antipsychotics for acute bipolar mania. Studies published through 2004 were identified using searches of PubMed/MEDLINE with the search terms mania, placebo, and each of the atypical antipsychotics, limited to randomized, controlled clinical trials; review of abstracts from the 2003 meetings of the American College of Neuropsychiatry, American Psychiatric Association, and International Conference on Bipolar Disorder; and consultations with study investigators and representatives of pharmaceutical companies that market atypical antipsychotics. Data Extraction: Analyses were performed on the changes in Young Mania Rating Scale or Mania Rating Scale total scores from baseline to endpoint, using last observation carried forward and computing the difference in change scores between each drug and its corresponding placebo arm. A random-effects model with fixed drug effects was used to combine the studies and make comparisons of the antipsychotics to each other and to placebo. Data Synthesis: Data from 12 placebo-controlled monotherapy and 6 placebo-controlled adjunctive therapy trials involving a total of 4304 subjects (including 1750 placebo-treated subjects) with bipolar mania were obtained. Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone all demonstrated significant efficacy in monotherapy (i.e., all confidence intervals exclude zero). However, after adjusting for multiple comparisons, pairwise comparisons of individual effects identified no significant differences in efficacy among antipsychotics. Magnitude of improvement was similar whether the antipsychotic was utilized as monotherapy or adjunctive therapy. Conclusions: The 5 newer atypical antipsychotics were all superior to placebo in the treatment of bipolar mania. For monotherapy and add-on therapy, cross-trial comparisons suggest that differences in acute efficacy between the drugs, if any, are likely to be small.

UR - http://www.scopus.com/inward/record.url?scp=33646781286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646781286&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 509

EP - 516

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -